Skip to main content

CORRECTION article

Front. Cell Dev. Biol., 16 October 2024
Sec. Cell Death and Survival
Volume 12 - 2024 | https://doi.org/10.3389/fcell.2024.1461581

Corrigendum: Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis

This article is a correction to:

  1. Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis

    1. Read original article
Christian Stoess,Christian Stoess1,2Aleksandra LeszczynskaAleksandra Leszczynska1Lin KuiLin Kui1Ariel E. Feldstein Ariel E. Feldstein1*
  • 1Department of Pediatric Gastroenterology, University of California, San Diego, San Diego, CA, United States
  • 2Department of Surgery, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

A Corrigendum on
Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis

by Stoess C, Leszczynska A, Kui L and Feldstein AE (2023). Front. Cell Dev. Biol. 11:1218807. doi: 10.3389/fcell.2023.1218807

In the published article, there was an error in the Conflict of interest statement-author, Ariel E. Feldstein was erroneously excluded. The corrected Conflict of interest statement appears below.

“Author AEF is an employee and stockholder of Novo Nordisk.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The author apologizes for this error and states that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: pyroptosis, gasdermins, liver, steatotic liver disease, steatohepatitis, MASH, MASLD

Citation: Stoess C, Leszczynska A, Kui L and Feldstein AE (2024) Corrigendum: Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis. Front. Cell Dev. Biol. 12:1461581. doi: 10.3389/fcell.2024.1461581

Received: 08 July 2024; Accepted: 10 July 2024;
Published: 16 October 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Stoess, Leszczynska, Kui and Feldstein. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ariel E. Feldstein, afeldstein@ucsd.edu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.